Exhaled nitric oxide in smokers and former smokers with chronic obstructive pulmonary disease

• Autorzy: Galiniak S. , Aebisher D. , Rachel M.
• Języki publikacji: EN

Abstrakty

EN

Background: Measurement of fractional exhaled nitric oxide (FeNO) is a useful technique for detection of eosinophilic airway inflammation and assessment of efficiency of corticosteroid treatment in patents with respiratory disease. Generally studies agree that measurement of FeNO is a useful non-invasive biomarker in patients with chronic obstructive pulmonary disease (COPD), however, there are reports that do not confirm such a relationship between FeNO and COPD. Aim of the study: The main objective of this study was to investigate FeNO levels in Polish patients with COPD compared to healthy controls. As a secondary objective, we assessed the influence of smoking on FeNO levels in healthy patients, and patients with COPD. Material and methods: FeNO concentration was measured using an electrochemical analyzer in healthy nonsmokers (n=21), healthy smokers (n=25), and former smokers with COPD (n=30) and smokers with COPD (n=38). General characteristics, hematological variables and serum biochemical parameters were also obtained and analyzed using the Kruskal-Wallis test. Results: FeNO measurement revealed significantly reduced NO levels in healthy smokers compared to healthy non-smokers, former smokers with COPD and smokers with COPD (median [range]: 14 [6–17] vs. 21 [15–29], 25 [15–53], and 19 [11–32] ppb, respectively, p<0.001). Moreover, we found increased FeNO levels in ex-smokers with COPD compared with smokers with COPD (p<0.05). No associations between FeNO and other analyzed parameters were found. Conclusions: Levels of FeNO, measured by with an electrochemical analyzer, were elevated among patients with COPD compared to healthy non-smoking controls. Moreover, our study confirms that smoking results in a reduction in FeNO concentration in both healthy patients and patients with COPD.

• Wydawca: -
• Czasopismo: Medical Science Pulse
• Rocznik: 2020
• Tom: 14
• Numer: 2
• Opis fizyczny: p.36-43,fig.,ref.

Twórcy

autor

Galiniak S.

• Medical College of Rzeszow University, Rzeszow, Poland

autor

Aebisher D.

• Medical College of Rzeszow University, Rzeszow, Poland

autor

Rachel M.

• Medical College of Rzeszow University, Rzeszow, Poland
• Allergology Outpatient Department, Provincial Hospital No 2, Rzeszow, Poland

Bibliografia

• 1. Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther Adv Respir Dis 2011; 5(3): 217–224.
• 2. Boukhenouna S, Wilson MA, Bahmed K, Kosmider B. Reactive oxygen species in chronic obstructive pulmonary disease. Oxid Med Cell Longev 2018; 2018: 5730395.
• 3. Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health Epidemiol Genom 2018; 3: e4.
• 4. Polverino F, Celli B. The challenge of controlling the COPD epidemic: unmet needs. Am J Med 2018; 131(9S): 1–6.
• 5. Kamal R, Srivastava AK, Kesavachandran CN. Meta-analysis approach to study the prevalence of chronic obstructive pulmonary disease among current, former and non-smokers. Toxicol Rep 2015; 2: 1064–1074.
• 6. Duong-Quy S, Vu-Minh T, Hua-Huy T, Tang-Thi-Thao T, LeQuang K, Tran-Thanh D, et al. Study of nasal exhaled nitric oxide levels in diagnosis of allergic rhinitis in subjects with and without asthma. J Asthma Allergy 2017; 10: 75–82.
• 7. Rachel M, Biesiadecki M, Aebisher D, Galiniak S. Exhaled nitric oxide in pediatric patients with respiratory disease. J Breath Res 2019; 13(4): 046007.
• 8. Wang Y, Li L, Han R, Lei W, Li Z, Li K, et al. Diagnostic value and influencing factors of fractional exhaled nitric oxide in suspected asthma patients. Int J Clin Exp Pathol 2015; 8(5): 5570–5576.
• 9. Brindicci C, Kharitonov SA, Ito M, Elliott MW, Hogg JC, Barnes PJ, et al. Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181(1): 21–30.
• 10. Jiang WT, Liu XS, Xu YJ, Ni W, Chen SX. Expression of nitric oxide synthase isoenzyme in lung tissue of smokers with and without chronic obstructive pulmonary disease. Chin Med J (Engl) 2015; 128(12): 1584–1589.
• 11. Lu Z, Huang W, Wang L, Xu N, Ding Q, Cao C. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta–analysis. Int J Chron Obstruct Pulmon Dis 2018; 13: 2695–2705.
• 12. Wedzicha JA, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017; 49(3): 1600791.
• 13. Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. American Thoracic Society Committee on interpretation of exhaled nitric oxide levels (FENO) for clinical applications. An official ats clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184(5): 602–615.
• 14. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force: standardisation of spirometry. Eur Respir J 2005; 26(2): 319–338.
• 15. Habib SS, Ahmed SM, Al Drees AM, Husain A. Effect of cigarette smoking on fractional exhaled nitric oxide in Saudi medical college students. J Pak Med Assoc 2011; 61(2): 120–123.
• 16. Malinovschi A, Janson C, Holmkvist T, Norbäck D, Meriläinen P, Högman M. Effect of smoking on exhaled nitric oxide and flow–independent nitric oxide exchange parameters. Eur Respir J 2006; 28(2): 339–345.
• 17. Corradi M, Majori M, Cacciani GC, Consigli GF, de’Munari E, Pesci A. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax 1999; 54(7): 572–575.
• 18. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 998–1002.
• 19. Santini G, Mores N, Shohreh R, Valente S, Dabrowska M, Trové A, et al. Exhaled and non–exhaled non–invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers. J Breath Res 2016; 10(1): 017102.
• 20. Zietkowski Z, Kucharewicz I, Bodzenta-Lukaszyk A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease. Respir Med 2005; 99: 816–824.
• 21. Rengasamy A, Johns RA. Regulation of nitric oxide synthase by nitric oxide. Mol Pharmacol 1993; 44: 124–128.
• 22. Beg MF, Alzoghaibi MA, Abba AA, Habib SS. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. Ann Thorac Med 2009; 4(2): 65–70.
• 23. Csoma B, Bikov A, Nagy L, Tóth B, Tábi T, Szűcs G, et al. Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD. Respir Res 2019; 20(1): 156.
• 24. Ichinose M, Sugiura H, Yamagata S, Koarai A, Shirato K. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med 2000; 162(2 Pt 1): 701–706.
• 25. Shrestha SK, Shrestha S, Sharma L, Pant S, Neopane A. Comparison of fractional exhaled nitric oxide levels in chronic obstructive pulmonary disease, bronchial asthma and healthy subjects of Nepal. J Breath Res 2017; 11(4): 047101.
• 26. Arif AA, Mitchell C. Use of exhaled nitric oxide as a biomarker in diagnosis and management of chronic obstructive pulmonary disease. J Prim Care Community Health 2016; 7(2): 102–106.
• 27. Alcázar‒Navarrete B, Ruiz Rodríguez O, Conde Baena P, Romero Palacios PJ, Agusti A. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J 2018; 51(1): 1701457.
• 28. Chen FJ, Huang XY, Liu YL, Lin GP, Xie CM. Importance of fractional exhaled nitric oxide in the differentiation of asthma–COPD overlap syndrome, asthma, and COPD. Int J Chron Obstruct Pulmon Dis 2016; 11: 2385–2390.
• 29. Guo Y, Hong C, Liu Y, Chen H, Huang X, Hong M. Diagnostic value of fractional exhaled nitric oxide for asthma-chronic obstructive pulmonary disease overlap syndrome. Medicine (Baltimore) 2018; 97(23): e10857.
• 30. Katoh S, Ikeda M, Shirai R, Abe M, Ohue Y, Kobashi Y, et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma 2018; 55(10): 1052–1058.
• 31. Arora S, Madan K, Mohan A, Kalaivani M, Guleria R. Serum inflammatory markers and nutritional status in patients with stable chronic obstructive pulmonary disease. Lung India 2019; 36: 393–398.
• 32. Hao W, Li M, Zhang C, Zhang Y, Du W. Increased levels of inflammatory biomarker CX3CL1 in patients with chronic obstructive pulmonary disease. Cytokine 2019; 126: 154881.
• 33. Baneen U, Naseem S. Correlation of severity of chronic obstructive pulmonary disease with serum vitamin-D level. J Family Med Prim Care 2019; 8: 2268–2277.
• 34. Jin J, Liu X, Sun Y. The prevalence of increased serum IgE and Aspergillus sensitization in patients with COPD and their association with symptoms and lung function. Respir Res 2014; 15(1): 130.
• 35. Brody DJ, Zhang X, Kit BK, Dillon CF. Reference values and factors associated with exhaled nitric oxide: U.S. youth and adults. Respir Med 2013; 107(11): 1682–1691.
• 36. Karrasch S, Ernst K, Behr J, Heinrich J, Huber RM, Nowak D, et al. KORA Study Group. Exhaled nitric oxide and influencing factors in a random population sample. Respir Med 2011; 105(5): 713–718.
• 37. Kim SH, Kim TH, Sohn JW, Yoon HJ, Shin DH, Park SS. Reference values and determinants of exhaled nitric oxide in healthy Korean adults. J Asthma 2010; 47(5): 563–567.
• 38. Taylor DR, Mandhane P, Greene JM, Hancox RJ, Filsell S, McLachlan CR, et al. Factors affecting exhaled nitric oxide measurements: the effect of sex. Respir Res 2007; 8(1): 82.
• 39. Gao J, Zhang M, Zhou L, Yang X, Wu H, Zhang J, et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis 2017; 12: 1287–1293.
• 40. Chou KT, Su KC, Huang SF, Hsiao YH, Tseng CM, Su VY, et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung 2014; 192(4): 499–504.

Identyfikatory

DOI

10.5604/01.3001.0014.2399